National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
NCT ID: NCT05326620
Last Updated: 2025-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2023-01-19
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Profiling in Prostate Cancer
NCT04983628
Renal Cell Carcinoma Microenvironment Discovery Project
NCT04005183
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
NCT07243067
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
NCT03630536
Follow-Up Study of Kidney Cancer Patients
NCT00656955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
localized RCC
all patients with localized RCC
No interventions assigned to this group
metastatic RCC
all patients with metastatic RCC, synchronous or metachronous
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* metachronous metastasized RCC
* age \>18 years
* capable of understanding Dutch language
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comprehensive Cancer Centre The Netherlands
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Ipsen
INDUSTRY
Pfizer
INDUSTRY
PROspective Renal Cancer Cohort Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adriaan Bins, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Amsterdam UMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amsterdam UMC locatie VUMC
Amsterdam, North Holland, Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
Meander Medisch Centrum
Amersfoort, , Netherlands
Gelre ziekenhuis
Apeldoorn, , Netherlands
Rijnstate
Arnhem, , Netherlands
Amphia Ziekenhuis
Breda, , Netherlands
Deventer Ziekenhuis
Deventer, , Netherlands
Albert Schweitzer
Dordrecht, , Netherlands
Catharina ziekenhuis
Eindhoven, , Netherlands
Maxima MC
Eindhoven, , Netherlands
Treant
Emmen, , Netherlands
UMCG
Groningen, , Netherlands
Spaarne Gasthuis
Haarlem, , Netherlands
Tergooi MC
Hilversum, , Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, , Netherlands
Maastricht UMC
Maastricht, , Netherlands
St Antonius Ziekenhuis
Nieuwegein, , Netherlands
Canisius Wilhelmina Ziekenhuis
Nijmegen, , Netherlands
Bravis ziekenhuis
Roosendaal, , Netherlands
Erasmus MC
Rotterdam, , Netherlands
Maasstad ziekenhuis
Rotterdam, , Netherlands
St. Franciscus ziekenhuis
Rotterdam, , Netherlands
Haaglanden Medisch Centrum
The Hague, , Netherlands
UMC Utrecht
Utrecht, , Netherlands
Viecuri
Venray, , Netherlands
Isala
Zwolle, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
A.D. Bins
Role: primary
T Smilde
Role: primary
Saskia van der Meer, MD PhD
Role: primary
JM van Dodewaard
Role: primary
D. Bochove
Role: primary
M. van den Berg
Role: primary
H Westgeest
Role: primary
A Imholz
Role: primary
J. van den Bosch
Role: primary
W Scheepens
Role: primary
M. Dercksen
Role: primary
B Knipscheer
Role: primary
S Oosting
Role: primary
S Dijkstra
Role: primary
H.P. van den Berg
Role: primary
B Rikhof
Role: primary
MJB Essers Aarts
Role: primary
K Herbschleb
Role: primary
S Dijkstra
Role: primary
E Collette
Role: primary
Paul Verhagen
Role: primary
Haberkorn
Role: primary
R Soest
Role: primary
L. de Vries
Role: primary
Tom Hermans, MD, PhD
Role: primary
M. Steffens
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Yildirim H, Widdershoven CV, Aarts MJ, Bex A, Bloemendal HJ, Bochove-Overgaauw DM, Hamberg P, Herbschleb KH, van der Hulle T, Lagerveld BW, van Oijen MG, Oosting SF, van Thienen JV, van der Veldt AA, Westgeest HM, Zeijdner EE, Aben KK, van den Hurk C, Zondervan PJ, Bins AD. The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs. BMC Cancer. 2023 Jul 11;23(1):648. doi: 10.1186/s12885-023-11094-9.
Related Links
Access external resources that provide additional context or updates about the study.
official study and foundation website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021_218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.